U.S. stock night trading volatility: Tempus AI announced strong performance and new contracts, rising 7.11% in night trading

U.S. Stock Night Market Movements Tempus AI rose 7.11% in the night market. Based on recent key news: On January 11, Tempus AI announced preliminary performance for the fourth quarter and the full year of 2025, with quarterly revenue of approximately $367 million, a year-on-year increase of about 83%. This strong financial performance drove the stock price up. On January 11, Tempus AI announced that its total contract value exceeded $1.1 billion, setting a new historical high. This news further enhanced market confidence in the company's future growth potential, promoting the rise in stock price. On January 11, Tempus AI signed data agreements with several pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, and Pfizer. The expansion of these partnerships demonstrates the company's influence in the industry, driving the stock price up. The AI healthcare industry is growing rapidly, with significant capital inflow. Stocks with High Trading Volume in the Industry Abcellera Biologics rose 6.41% in the night market. Based on recent news, On January 12, MarketBeat pointed out that AbCellera Biologics was not included in the list of five stocks recommended by top analysts, despite its rating remaining unchanged, which may affect investor confidence and lead to stock price fluctuations. No other significant news recently. The biotechnology industry has been volatile recently and requires attention. Ginkgo Bioworks rose 2.49% in the night market. Based on recent key news: On January 9, TD Cowen lowered the target price for Ginkgo Bioworks from $14 to $12. This move reflects market concerns about the company's future profitability, leading to stock price fluctuations. U.S. stocks have been more volatile recently, requiring attention to risks. Illumina fell 0.74% in the night market. Based on recent news, On January 8, Illumina announced that its Chief Commercial Officer, Everett Cunningham, would resign on January 16. This news raised market concerns about the stability of the company's management, leading to a decline in stock price. On January 9, Illumina appointed Dr. Eric Green as Chief Medical Officer. Although the new appointment aims to strengthen the company's leadership team, the market's reaction to the management changes remains negative, further impacting the stock price. On January 10, Quanterix announced that it would exceed its revenue and cash guidance for 2025, causing its stock price to surge. This news indirectly affected Illumina's market performance, as investors may shift funds to better-performing companies. The biotechnology industry has been volatile recently, and investors should exercise caution